Ayala

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Research, RLT, FAP, Ayala, NDA, Acquisition, Executive Committee, Spacecraft, PIPE, Phase 3, Pharmacology, ADC, Pharmaceutical industry

We expect to add novel antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) to the pipeline through internal discovery efforts while continuing to evaluate opportunities to acquire high-quality assets on favorable financial terms.

Key Points: 
  • We expect to add novel antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) to the pipeline through internal discovery efforts while continuing to evaluate opportunities to acquire high-quality assets on favorable financial terms.
  • Immunome expects to report topline data for the ongoing Phase 3 RINGSIDE Part B trial of AL102 in the first quarter of 2025.
  • In parallel, Immunome is evaluating and performing additional manufacturing and pharmacology work required to support an NDA submission of AL102.
  • Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Ayala, OTCQX, Plantar fibromatosis, Pharmaceutical industry

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.
  • Earlier this month, Immunome announced that it entered into a definitive asset purchase agreement with Ayala to acquire AL102 and related drug candidate AL101.
  • “We are pleased with the progress of the RINGSIDE trial,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.
  • “The robust enrollment of the Phase 3 portion affirms our excitement for the potential of AL102.

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

Retrieved on: 
Thursday, October 19, 2023
Neoplasm, Ayala, LLM, OTCQX, CPA, Plantar fibromatosis, Doctor of Philosophy, MBA, Master of Science, CFO, Chief medical informatics officer, FACP, Berlin, AML, Pharmaceutical industry, Management, MD

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight.

Key Points: 
  • REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight.
  • The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala’s current ticker symbol (“ADXS”).
  • “We are pleased to close the merger with Biosight which expands our product pipeline,” said Ken Berlin, President & CEO.
  • Roy Golan, CPA, LLM, previously Executive VP & CFO of Biosight, has been appointed Chief Financial Officer of the combined company.

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Columbia University, ACC, Plantar fibromatosis, Financial result, ESMO, Survival, Adenoid cystic carcinoma, ASCO, Congress, American Society of Clinical Oncology, Patient, OTCQX, Ayala, Security (finance), European Society for Medical Oncology, Research, FDA, Berlin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PSA, Society, Food, Prostate cancer, Pharmaceutical industry, Rare-earth element, Clothing

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.

Key Points: 
  • Definitive merger agreement with Biosight, expected to close near end of Q3 2023
    REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.
  • Gain clarity on path for future development plan for AL101 in recurrent/metastatic adenoid cystic carcinoma (R/M ACC), expected in 2023.
  • Consolidated Financial Results for the Second Quarter Ended June 30, 2023
    Cash position On June 30, 2023, the Company’s consolidated cash and cash equivalents position was $7.1 million.
  • For further details on the Company’s financial results, including results for the six-month period ended June 30, 2023, refer to our quarterly report on Form 10-Q for the quarter ended June 30,2023, filed with the Securities and Exchange Commission.

Philippines' Globe receives overwhelming support for PHP17B rights offer

Retrieved on: 
Wednesday, November 9, 2022
Face, Human, United Nations Global Compact, Company, Technology, Science and technology in Asia, THIS, PSE, Securities Act of 1933, Ayala, Domestic, UBS, Association of British HealthTech Industries, Internet, Philippine Stock Exchange, Partnership, Telecommunication, Information technology, Ayala Corporation, Solution, GLO, Sale, Security (finance), Bank, Financial services, Globe, Singtel

MANILA, Philippines, Nov. 9, 2022 /PRNewswire/ -- Leading Philippine digital solutions platform Globe (PSE: GLO) has received overwhelming shareholder support for its first rights offer in over two decades, raising gross proceeds of approximately 17 billion.

Key Points: 
  • MANILA, Philippines, Nov. 9, 2022 /PRNewswire/ -- Leading Philippine digital solutions platform Globe (PSE: GLO) has received overwhelming shareholder support for its first rights offer in over two decades, raising gross proceeds of approximately 17 billion.
  • The offer marks the triumphant return of Globe to equity capital markets since it last raised equity from its shareholders.
  • Even in the face of market headwinds, the rights offer was oversubscribed and all the offer shares were fully allocated to existing shareholders.
  • This support reflects trust in the capability of Globe to execute our core business and digital service platform initiatives.

Cellebrite Appoints Adv. Ayala Berler Shapira as General Counsel

Retrieved on: 
Monday, October 3, 2022
Solution, GLOBE, Digital intelligence, Review, Nasdaq, Privacy, New York State Bar Association, Compliance, Twitter, GC, Head, Leadership, General counsel, DI, Organization, Tel Aviv University, Ayala, Digital, Risk management, Online gambling, Cellebrite, Amdocs

PETAH TIKVA, Israel and TYSONS CORNER, Va., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced that Ayala Berler Shapira has been named General Counsel (GC) of the company.

Key Points: 
  • PETAH TIKVA, Israel and TYSONS CORNER, Va., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced that Ayala Berler Shapira has been named General Counsel (GC) of the company.
  • As part of the companys further growth Ayala Berler Shapira will strategically manage all legal aspects and will assume complete responsibility and lead the legal and compliance organization of Cellebrite.
  • Ayala brings 27 years of experience in both global technology companies and in some of the leading law firms in Israel.
  • Yossi Carmil, Chief Executive Officer of Cellebrite, comments: We are thrilled to have Ayala join the Cellebrite family and management team.

Piper Ayala, a Pioneer in the Corporate Housing Industry Retiring

Retrieved on: 
Tuesday, April 19, 2022
Corporate housing, VP, ExecuStay, Piper, Goal, Pleasure, Growth, Region, Marriott International, Heart, Ayala, Retirement, City, Industry, Acquisition, Australian Transit Group, CHPA, ESOP, Management

WICHITA, Kan., April 19, 2022 /PRNewswire-PRWeb/ -- Since 1992, Piper Ayala, Vice President at ExecuStay Midwest, has been at the forefront of the corporate housing industry. This fall, she will be taking on a new adventure—retirement.

Key Points: 
  • WICHITA, Kan., April 19, 2022 /PRNewswire-PRWeb/ -- Since 1992, Piper Ayala , Vice President at ExecuStay Midwest , has been at the forefront of the corporate housing industry.
  • In 1992, Ayala joined Suite Options (now known as ExecuStay Midwest), the corporate housing division of Transitions Group, Inc.
  • They were pioneers in the corporate housing industry, and leaders in the Corporate Housing Providers Association (CHPA).
  • Her favorite memories will always be the people she's had the pleasure to work with at ExecuStay and in the corporate housing industry.

Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 10, 2021
Cancer, T-Cell Acute Lymphoblastic Leukemia, T-ALL, TNBC, Novartis, NASDAQ, Plantar fibromatosis, ACC, MM, GMT, Patient, Neoplasm, Conference, Ayala, GLOBE, Event, Therapy, Multiple myeloma, Webcast, Adenoid cystic carcinoma, AYLA, FDA, Pharmaceutical industry

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).
  • A live webcast of the fireside chat may be accessed by visiting the Events & Presentations section of Ayalas website at ir.ayalapharma.com .
  • An archived replay of the webcast will be available on the website for approximately 90 days following the presentations.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.

AI Phishing Defense Leader SlashNext Closes $26 Million Series B Funding

Retrieved on: 
Thursday, October 28, 2021
Accounting, Technology, SASE, Industry, IR, Tablet, Ayala, Globe Telecom, SEG, Organization, Software as a service, Health, Adoption, Transport, Original equipment manufacturer, Machine learning, American Defense Service Medal, URL, MS, Communication, VAR, Time, Life, Senior, MSSP, Hotel manager, Growth, Work, Phishing, API, ARR, Acquisition, Proxy, BEC, Cryptocurrency, Online shopping

PLEASANTON, Calif., Oct. 28, 2021 /PRNewswire/ -- SlashNext , the leader in SaaS-based spear-phishing and human hacking defense across digital channels and apps, today announced it raised $26 million in Series B venture capital funding.

Key Points: 
  • PLEASANTON, Calif., Oct. 28, 2021 /PRNewswire/ -- SlashNext , the leader in SaaS-based spear-phishing and human hacking defense across digital channels and apps, today announced it raised $26 million in Series B venture capital funding.
  • SlashNext's patented cloud and on-device AI goes beyond email protection, and stops spear phishing, social engineering, and other targeted human threats across popular communication channels and collaboration apps.
  • "When cybercriminals launch successful multi-channel phishing and social engineering attacks, the results are massively disruptive to people, organizations, and the economy," said Patrick Harr, SlashNext CEO.
  • SlashNext 360 Defense Service utilizes our patented AI SEERTMtechnology to detect zero-hour phishing threats by performing dynamic run-time analysis on billions of URLs a day through virtual browsers and machine learning.

AI Phishing Defense Leader SlashNext Closes $26 Million Series B Funding

Retrieved on: 
Thursday, October 28, 2021
Accounting, Technology, SASE, Industry, IR, Tablet, Ayala, Globe Telecom, SEG, Organization, Software as a service, Health, Adoption, Transport, Original equipment manufacturer, Machine learning, American Defense Service Medal, URL, MS, Communication, VAR, Time, Life, Senior, MSSP, Hotel manager, Growth, Work, Phishing, API, ARR, Acquisition, Proxy, BEC, Weapon, Cryptocurrency, Online shopping

PLEASANTON, Calif., Oct. 28, 2021 /PRNewswire/ -- SlashNext, the leader in SaaS-based spear-phishing and human hacking defense across digital channels and apps, today announced it raised $26 million in Series B venture capital funding. With new investors Tom and Matt Gallo, Telia Group, and the ACTIVE Fund of the Ayala group, and participation from early investors Norwest, Wing, and Alter Ventures, the round brings SlashNext's total funding to $43 million. Thomas Gallo also joins the SlashNext board of directors.

Key Points: 
  • Funding will accelerate the company's mission to protect the world's 4B Internet users from all forms of phishing - the number one, multi-billion-dollar cybersecurity threat to organizations and consumers
    PLEASANTON, Calif., Oct. 28, 2021 /PRNewswire/ -- SlashNext , the leader in SaaS-based spear-phishing and human hacking defense across digital channels and apps, today announced it raised $26 million in Series B venture capital funding.
  • SlashNext's patented cloud and on-device AI goes beyond email protection, and stops spear phishing, social engineering, and other targeted human threats across popular communication channels and collaboration apps.
  • "When cybercriminals launch successful multi-channel phishing and social engineering attacks, the results are massively disruptive to people, organizations, and the economy," said Patrick Harr, SlashNext CEO.
  • SlashNext 360 Defense Service utilizes our patented AI SEERTMtechnology to detect zero-hour phishing threats by performing dynamic run-time analysis on billions of URLs a day through virtual browsers and machine learning.